Star of the Securities, Kexing Pharmaceutical will soon release an annual report of 2023. According to the performance report released on February 23, the loss of net profit attributable to 189.6 million yuan, a decrease of 109.95%year -on -year.
Instructions on the performance and financial status of the performance Express:
(1) Reporting periodThe main factors of business conditions, financial status, and the main factors affecting operating performance
During the reporting period, the company realized operating income of 125,90,600 yuan, a year -on -year decrease of 4.32%; net profit attributable to shareholders of listed companies-1895.733 million yuan, a year-on-year decrease of 99.2781 million yuan; net profit of non-recurring profit and loss of non-recurring profit and loss attributable to shareholders of listed companies was-20.084 million yuan, a year-on-year decrease of 104.237 million yuan.Some products of the company are affected by regional collection, and the decline in sales unit prices has decreased slightly, but the sales of related products have maintained their growth and continued to maintain a leading position in domestic market segments.At the same time, the companys sales costs and production costs have decreased compared with the same period of the previous year by strengthening the lean management of the entire business process.The clinical trials of multiple R & D projects in the company have steadily advanced, and the comprehensive strength of R & D has significantly improved.
The main reason for the reporting of the shareholders of listed companies is due to increasing R & D costs and financial expenses.
(2) The main reasons for the increase or decrease of the project in the above table above 30%
During the reporting period, the companys operating profit, Total profit, net profit attributable to shareholders of listed companies, and deducting net profit of non -recurring profit and loss belonging to the shareholders of listed companies. Basic earnings per share decreased by more than 30%compared with the same period of the previous year.For the increase in investment and financial expenses, please refer to the part of this section (1) in detail.
(3) Other instructions
The company continues to strengthen channel construction and expand market coverage. As of the disclosure of this announcement, the companys preliminary statistics, the companys preliminary statistics, the company,In 2024, the companys product shipment growth rate was obvious. The number of domestic delivery in China increased by more than 50%year -on -year, and successfully achieved the "opening of the door".
Kexing Pharmaceutical (688136) Main business: It is mainly engaged in the development, production, and sales of reorganized protein drugs and micro -ecological preparationsAnti -virus, tumor and immunity, blood, digestion, degenerative diseases and other treatment fields, are currently developing in the technical direction of new protein, new antibodies, nucleic acid drugs, etc., and are committed to serving global patients with biotechnology and become high -quality biopharmaceutical leadership.By.
The stock has given rating a total of 3 institutions in the last 90 days, buying 1 rating, and increasing 2 rating.
The above content is compiled by the securities star based on public information, which is generated by the algorithm and has nothing to do with the position of this site.The Star of the Securities strives but does not guarantee the accuracy, integrity, validity, timeliness, etc. of all or part of the information (including but not limited to text, video, audio, data, and charts). Please contact us if there are problems.This article is data finishing, and does not constitute any investment advice to you. Investment is risky. Please decide carefully.
